Table 2.
Frequency and odds ratio (OR) for thrombosis within the different serologic subgroups in aPL carriers. The OR were calculated taking as a reference category those patients positive only for aCL IgG
| aPL serology | No. of patients | No. of thrombosis (%) | OR | p |
|---|---|---|---|---|
| aCL IgG (reference category) | 38 | 2 (5.3) | ||
| aCL Ig M | 30 | 2 (6.7) | 1.29 | 0.807 |
| aCL IgG + aCL IgM | 9 | 2 (22.2) | 5.14 | 0.130 |
| AB2GPI IgG | 7 | 1 (14.3) | 3.00 | 0.399 |
| AB2GPI IgM | 3 | 0 (0.0) | - | 0.999 |
| AB2GPI IgG + AB2GPI IgG | 1 | 0 (0.0) | - | 1.00 |
| aCL + LA | 13 | 1 (7.7) | 1.50 | 0.749 |
| aCL + AB2GPI | 23 | 1 (4.3) | 0.82 | 0.873 |
| aCL + AB2GPI + LA | 13 | 4 (30.8) | 8.00 | 0.027 |
| AB2GPI + LA | 1 | 0 (0.0) | - | 1.00 |
| Total | 138 | 13 (9.4) |
No. number, aPL antiphospholipid antibodies, aCL anticardiolipin antibodies, AB2GPI antibeta 2 glycoprotein antibodies, LA lupus anticoagulant